The trademark application Dosiba Intellidose was filed by Novo Nordisk A/S, a corporation established under the laws of the Kingdom of Denmark (the "Applicant"). The application was published for oppositions on February 23, 2021, and it was registered by office on June 2, 2021 without any oppositions.
The application was filed in Danish (English was selected as the second language).